Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugsWSJ • 07/21/26
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?The Motley Fool • 07/20/26
The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBC • 07/19/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1The Motley Fool • 07/18/26
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight LossThe Motley Fool • 07/18/26
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still WinThe Motley Fool • 07/17/26
IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three MonthsInvestors Business Daily • 07/17/26
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu's Fashion Considers Strategic AlternativesBenzinga • 07/17/26
Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion DealInvestors Business Daily • 07/17/26
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says JefferiesProactive Investors • 07/17/26